Italia markets open in 1 hour 21 minutes

Organovo Holdings, Inc. (0R02.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,5216-0,0828 (-5,16%)
Alla chiusura: 02:59PM GMT
Schermo intero
Chiusura precedente1,6044
Aperto0,0000
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume4.200
Media VolumeN/D
Capitalizzazione851.671
Beta (5 anni mensile)1,04
Rapporto PE (ttm)N/D
EPS (ttm)-1,3150
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

    SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its first inflammatory bowel disease (IBD) model and has achieved the next milestone, target validation. The company announced in May 2022 that it had achieved a successful Crohn’s disease model

  • GlobeNewswire

    Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

    SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Executive Chairman, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022. Organovo plans to advance drugs discovered in its cutting-edge human 3D disease models in inflammatory bowel dis

  • GlobeNewswire

    Organovo Announces Postponement of Annual Meeting of Stockholders

    SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease (the “Company”), today announced that its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) that was scheduled to be held at 9:00AM (Pacific Time) on Wednesday, September 7, 2022 has been postponed to October 12, 2022 at 9:00AM (Pacific Time), a date determined